![PDF] Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload | Semantic Scholar PDF] Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7c49c2cf364442a61fe35e998eeb8f932c747af0/2-Figure1-1.png)
PDF] Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload | Semantic Scholar
![Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-31601-z/MediaObjects/41467_2022_31601_Fig1_HTML.png)
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications
![hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer | Journal of Medicinal Chemistry hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.3c01210/asset/images/medium/jm3c01210_0008.gif)
hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer | Journal of Medicinal Chemistry
![Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer | British Journal of Cancer Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-020-01046-6/MediaObjects/41416_2020_1046_Fig1_HTML.png)
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer | British Journal of Cancer
![Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11095-021-03162-1/MediaObjects/11095_2021_3162_Fig3b_HTML.png)
Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research
![Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6927763/bin/kmab-12-01-1699768-g001.jpg)
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC
![Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523423004555-ga1.jpg)
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect
Generation of the potent antibody-drug conjugate trastuzumab-(LAP·MMAE)... | Download Scientific Diagram
![Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | Nature Communications Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-23793-7/MediaObjects/41467_2021_23793_Fig1_HTML.png)
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | Nature Communications
![Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry](https://pubs.acs.org/cms/10.1021/acs.bioconjchem.2c00015/asset/images/large/bc2c00015_0002.jpeg)
Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry
![Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety](https://www.mdpi.com/cancers/cancers-12-00744/article_deploy/html/images/cancers-12-00744-g001.png)
Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety
![Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog](https://www.creative-biolabs.com/blog/adc/wp-content/uploads/2018/03/MMAE-and-MMAF.png)
Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog
![Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics](https://www.creative-diagnostics.com/upload/image/Anti-MMAE-Antibodies-and-Conjugates-For-PKPD-Studies-on-MMAE-ADC-1.png)
Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics
![Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety](https://pub.mdpi-res.com/cancers/cancers-12-00744/article_deploy/html/images/cancers-12-00744-g001-550.jpg?1585802265)
Cancers | Free Full-Text | Antibody-Drug Conjugate Using Ionized Cys-Linker- MMAE as the Potent Payload Shows Optimal Therapeutic Safety
![Preparation of the Val‐Cit‐MMAE antibody‐drug conjugate (ADC) and drug... | Download Scientific Diagram Preparation of the Val‐Cit‐MMAE antibody‐drug conjugate (ADC) and drug... | Download Scientific Diagram](https://www.researchgate.net/publication/346364830/figure/fig4/AS:11431281179314321@1691171185097/Preparation-of-the-Val-Cit-MMAE-antibody-drug-conjugate-ADC-and-drug-antibody-ratio-of.png)